Lenacapavir, a groundbreaking HIV prevention drug, is set to roll out in Africa, with Eswatini becoming the first country to receive this twice-yearly injection. Initial doses have already been delivered to Zambia and Eswatini as part of a larger initiative led by Gilead and its partners to distribute the drug across Sub-Saharan Africa. However, there has been controversy regarding the exclusion of South Africa, the nation most affected by HIV, from the initial rollout. The Trump administration has faced criticism for its decision to not include South Africa in the distribution plan, raising concerns about equitable access to crucial HIV prevention methods.